MA52966A - Anticorps anti-facteur xii/xiia et leurs utilisations - Google Patents

Anticorps anti-facteur xii/xiia et leurs utilisations

Info

Publication number
MA52966A
MA52966A MA052966A MA52966A MA52966A MA 52966 A MA52966 A MA 52966A MA 052966 A MA052966 A MA 052966A MA 52966 A MA52966 A MA 52966A MA 52966 A MA52966 A MA 52966A
Authority
MA
Morocco
Prior art keywords
xiia
antibodies
factor xii
xii
factor
Prior art date
Application number
MA052966A
Other languages
English (en)
Inventor
Dan Chalothorn
Kehdih Lai
Lyndon Mitnaul
Lori C Morton
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA52966A publication Critical patent/MA52966A/fr

Links

Classifications

    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/45—Differential amplifiers
    • H03F3/45071—Differential amplifiers with semiconductor devices only
    • H03F3/45076—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier
    • H03F3/45475—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier using IC blocks as the active amplifying circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2203/00—Indexing scheme relating to amplifiers with only discharge tubes or only semiconductor devices as amplifying elements covered by H03F3/00
    • H03F2203/45—Indexing scheme relating to differential amplifiers
    • H03F2203/45444—Indexing scheme relating to differential amplifiers the CMCL comprising a sample and hold circuit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Amplifiers (AREA)
MA052966A 2018-06-19 2019-06-19 Anticorps anti-facteur xii/xiia et leurs utilisations MA52966A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687144P 2018-06-19 2018-06-19

Publications (1)

Publication Number Publication Date
MA52966A true MA52966A (fr) 2021-04-28

Family

ID=67263076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052966A MA52966A (fr) 2018-06-19 2019-06-19 Anticorps anti-facteur xii/xiia et leurs utilisations

Country Status (12)

Country Link
US (1) US12068729B2 (fr)
EP (1) EP3810270A1 (fr)
JP (2) JP7634993B2 (fr)
KR (1) KR20210022650A (fr)
CN (1) CN112437682B (fr)
AU (1) AU2019288299B2 (fr)
CA (1) CA3104470A1 (fr)
EA (1) EA202190056A1 (fr)
IL (1) IL279529A (fr)
MA (1) MA52966A (fr)
MX (1) MX2020013894A (fr)
WO (1) WO2019246176A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
IL298989A (en) * 2020-07-03 2023-02-01 CSL Innovation Pty Ltd High concentration promotion of factor XII antigen binding proteins
EP4729546A1 (fr) * 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Anticorps reconnaissant de manière spécifique le facteur xiia et son utilisation
KR20260042526A (ko) * 2023-07-19 2026-03-31 리제너론 파아마슈티컬스, 인크. 항-인자 XII/XIIa 항체 및 이의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
AU7793291A (en) * 1990-05-10 1991-11-27 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7378867B1 (en) * 2002-06-04 2008-05-27 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US6891394B1 (en) * 2002-06-04 2005-05-10 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (fr) 2004-04-20 2013-11-06 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
CN101102819A (zh) 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7541838B2 (en) * 2007-03-27 2009-06-02 Intel Corporation Transmitter swing control circuit and method
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EP2371857A1 (fr) 2010-04-01 2011-10-05 CSL Behring GmbH Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel
EP2384766A1 (fr) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Nouvel anticorps pour anhydrase carbonique
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (fr) 2011-03-09 2012-09-12 CSL Behring GmbH Inhibiteur du facteur XII pour le traitement de la pénombre ischémique cérébrale et l'ischémie d'autres organes
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
HRP20250164T1 (hr) * 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR101461652B1 (ko) * 2011-12-16 2014-11-21 주식회사 삼양바이오팜 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법
EP2623110A1 (fr) 2012-01-31 2013-08-07 CSL Behring GmbH Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
TWI613215B (zh) * 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2014089493A1 (fr) * 2012-12-07 2014-06-12 Vanderbilt University Anticorps contre le facteur xii et leurs utilisations
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
KR20150139089A (ko) * 2014-06-02 2015-12-11 한국전자통신연구원 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로
AU2015340056A1 (en) * 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
US11405242B2 (en) * 2018-07-02 2022-08-02 Rambus Inc. Methods and circuits for decision-feedback equalization with early high-order-symbol detection

Also Published As

Publication number Publication date
JP2024116399A (ja) 2024-08-27
US20210203292A1 (en) 2021-07-01
JP2021527424A (ja) 2021-10-14
CN112437682A (zh) 2021-03-02
WO2019246176A8 (fr) 2020-10-08
IL279529A (en) 2021-01-31
AU2019288299B2 (en) 2026-02-05
CA3104470A1 (fr) 2019-12-26
JP7634993B2 (ja) 2025-02-25
EP3810270A1 (fr) 2021-04-28
US12068729B2 (en) 2024-08-20
WO2019246176A1 (fr) 2019-12-26
KR20210022650A (ko) 2021-03-03
AU2019288299A1 (en) 2021-01-14
EA202190056A1 (ru) 2021-05-28
CN112437682B (zh) 2024-11-05
MX2020013894A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3849608A4 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
EP3924389A4 (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP4048699A4 (fr) Anticorps multispécifiques anti-pd-l1/anti-b7-h3 et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP4010368A4 (fr) Anticorps anti-nampt et leurs utilisations
EP3947462A4 (fr) Anticorps anti-galectine-9 et leurs utilisations